|
Univariate analysis
|
Multivariate analysis 1
|
|
Age, year
|
1.024
|
1.000–1.050
|
0.0481
|
Age, year
|
1.003
|
0.978–1.029
|
0.8402
|
|
Gender, male
|
1.054
|
0.652–1.624
|
0.8218
|
Gender, male
|
1.455
|
0.905–2.438
|
0.1365
|
|
History of AE, yes
|
2.413
|
1.518–3.677
|
< 0.0001
|
History of AE, yes
|
1.062
|
0.602–1.777
|
0.8268
|
|
Pirfenidone
|
1.002
|
0.694–1.425
|
0.9892
|
BMI, per 1 kg/m2 increase
|
0.956
|
0.904–1.009
|
0.1051
|
|
Period: Diagnosis-administration
|
1.001
|
0.996–1.005
|
0.7124
|
FVC, per 1% increase
|
0.978
|
0.967–0.989
|
0.0001
|
|
BMI, per 1 kg/m2 increase
|
0.905
|
0.860–0.953
|
0.0001
|
LTOT, yes
|
1.774
|
1.205–2.590
|
0.0032
|
|
FVC,per 1% increase
|
0.970
|
0.959–0.980
|
< 0.0001
|
Patients with IPF who switched antifibrotics
|
0.392
|
0.221–0.656
|
0.0007
|
|
FEV1, per 1% increase
|
0.989
|
0.979–0.999
|
0.0261
|
Multivariate analysis 2
|
|
FEV1/FVC, per 1% increase
|
1.061
|
1.038–1.089
|
< 0.0001
|
Age, year
|
1.005
|
0.979–1.032
|
0.7131
|
|
DLCO, per 1% increase
|
0.974
|
0.962–0.986
|
< 0.0001
|
Gender, male
|
1.536
|
0.940–2.618
|
0.0992
|
|
TP, per 1 g/dl increase
|
0.978
|
0.763–1.271
|
0.8647
|
History of AE, yes
|
1.214
|
0.684–2.267
|
0.5247
|
|
Alb, per 1 g/dl increase
|
0.601
|
0.411–0.896
|
0.0105
|
BMI, per 1 kg/m2 increase
|
0.940
|
0.883–0.997
|
0.0440
|
|
KL-6, per 1 U/ml increase
|
1.000
|
1.000–1.000
|
0.0003
|
FVC, per 1% increase
|
0.980
|
0.968–0.991
|
0.0007
|
|
SP-D, per 1 ng/ml increase
|
1.001
|
1.000–1.002
|
0.0510
|
KL-6, per 1 U/ml increase
|
1.000
|
1.000–1.000
|
0.0217
|
|
LTOT, yes
|
2.575
|
1.847–3.574
|
< 0.0001
|
LTOT, yes
|
1.660
|
1.103–2.468
|
0.0135
|
|
Patients with IPF who switched antifibrotics
|
0.318
|
0.182–0.506
|
< 0.0001
|
Patients with IPF who switched antifibrotics s
|
0.374
|
0.206–0.638
|
0.0006
|
|
Switching antifibrotics (time dependent covariate)
|
0.895
|
0.517–1.550
|
0.692
| | | | |
